Cardiac allograft vasculopathy epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 21: Line 21:
* The survival curve demonstrates a steep fall in survival in the first 6 months post-transplant. Thereafter, it steadily decreases by 3.5% per year and continues to do so well beyond 15 years. However, the risk adjusted Kaplan-Meier curves suggests a significant improvement in long term survival in recent years.  
* The survival curve demonstrates a steep fall in survival in the first 6 months post-transplant. Thereafter, it steadily decreases by 3.5% per year and continues to do so well beyond 15 years. However, the risk adjusted Kaplan-Meier curves suggests a significant improvement in long term survival in recent years.  
* Re-transplantation: Patients who underwent re-transplantation between 2002 to 2006, who were more than 12 months from their index transplantation had a 1 year survival of approximately 85%, which is the same as index transplants performed during that period.
* Re-transplantation: Patients who underwent re-transplantation between 2002 to 2006, who were more than 12 months from their index transplantation had a 1 year survival of approximately 85%, which is the same as index transplants performed during that period.
===Causes of death===


==References==
==References==

Revision as of 16:51, 28 September 2014

Cardiac allograft vasculopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Cardiac allograft vasculopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Coronary Angiography

Intravascular Ultrasound

Optical Coherence Tomography

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac allograft vasculopathy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac allograft vasculopathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac allograft vasculopathy epidemiology and demographics

CDC on Cardiac allograft vasculopathy epidemiology and demographics

Cardiac allograft vasculopathy epidemiology and demographics in the news

Blogs on Cardiac allograft vasculopathy epidemiology and demographics

Directions to Hospitals Treating Cardiac allograft vasculopathy

Risk calculators and risk factors for Cardiac allograft vasculopathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]

Overview

As per data from the Registry of the International Society of Heart and Lung transplantation[1], the number of reported heart transplants has increased slowly in the recent years, especially in North America.

Epidemiology and Demographics

Donor demographics and characteristics

  • In the recent cohort from the ISHLT (International Registry of Heart and Lung Transplant)[1], 69% of the donors are male and the incidence of female donor to male recipient transplantation is seen less frequently than previously.
  • Average donor age is 34 years whereas average donor recipient age difference is 16 years.
  • The leading cause of donor death was head trauma (46%) whereas the second most common cause was stroke (24%). Donor diabetes and hypertension is rare but increasing steadily. Average ischemia time was 3.3 hours (range 1.6 to 5.1 hours).

Recipient demographics and characteristics

  • Cardiomyopathy and coronary artery disease are the most frequent diagnoses leading to a heart transplant. The proportion of recipients with history of cardiomyopathy is increasing over time.
  • Increasing proportions of high risk patients like re-transplants, congenital heart diseases, co-morbidities like diabetes mellitus, hypertension, prior history of dialysis, previous malignancy and previous cardiac surgery reflect changes in patient characteristics over time. Also the use of left ventricular assist devices (LVAD's) in the interim period as a bridge to transplant has increased over time (28%).
  • The average recipient age has stayed stable at 54 years in the last decade whereas the proportion of male recipients has decreased over years from 81% in 1992- 2000 to 76% in 2006- 2012.

Survival

  • Overall data from 1982 up to June 2011 shows 1 year survival of 81% and 5 year survival of 69%, with median survival of 10 years for all and 13 years for those surviving until the end of first year. The most recent cohort of patients show unadjusted 1 year survival of 84%.
  • The survival curve demonstrates a steep fall in survival in the first 6 months post-transplant. Thereafter, it steadily decreases by 3.5% per year and continues to do so well beyond 15 years. However, the risk adjusted Kaplan-Meier curves suggests a significant improvement in long term survival in recent years.
  • Re-transplantation: Patients who underwent re-transplantation between 2002 to 2006, who were more than 12 months from their index transplantation had a 1 year survival of approximately 85%, which is the same as index transplants performed during that period.

Causes of death

References

  1. 1.0 1.1 Taylor DO, Edwards LB, Boucek MM, Trulock EP, Aurora P, Christie J; et al. (2007). "Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007". J Heart Lung Transplant. 26 (8): 769–81. doi:10.1016/j.healun.2007.06.004. PMID 17692781.

Template:WS Template:WH